Lantern Pharma earnings were -$13.8M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest LTRN earnings report on Sep 30, 2026 announced Q3 2026 earnings of $696.6k, down 109.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LTRN reported annual earnings of -$17.1M, with -17.6% growth.
On LTRN's earnings call on Nov 17, 2026, Lantern Pharma (NASDAQ: LTRN) reported Q3 2026 earnings per share (EPS) of $0.05, up 112.82% year over year. Total LTRN earnings for the quarter were $696.62 thousand. In the same quarter last year, Lantern Pharma's earnings per share (EPS) was -$0.39.
As of the last Lantern Pharma earnings report, Lantern Pharma is currently losing money. Lantern Pharma's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$13.78 million, a 27.17% decrease year over year.
What was LTRN's earnings growth in the past year?
As of Lantern Pharma's earnings date in Nov 17, 2026, Lantern Pharma's earnings has grown year over year. LTRN earnings in the past year totalled -$13.78 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.